QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Bausch Health Companies Inc. (BHC)

Healthcare

Actionable
Fundamental
3
Sentiment
3
Technical
4

Buy limit 8.10 GTC — a pullback bid to the 8.02–8.14 shelf inside a stacked uptrend (price above SMA20/50/200, ADX 33 rising) — with a protective stop at 7.68 (below the 11-03 swing low 7.87, floored at 1.0×ATR), targets 8.94/9.57 and R/R 2.00; the alternative breakout stop above the settled 8.46 high was rejected at R/R 1.22 running into the 9.04 catalyst-day resistance.

Analysis as of 2026-11-05· more than 2 trading days ago

Company overview

Bausch Health Companies Inc. develops, manufactures, and commercializes pharmaceuticals, medical devices, and over-the-counter products, focusing on ophthalmology, digestive health, and dermatology. It operates through divisions like Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products, with a global presence.

Fundamental

fair
Fundamental3
Mixed fundamentals

Bausch Health shows strong cash generation but faces leverage constraints and a looming patent cliff.

Mixed, cash-rich, leverage-constrained: Bausch Health generates roughly $1.8 billion of free cash flow a year with 72% gross margins and improving 2026 interim revenue and segment profit, but carries about $18 billion of net debt against negative shareholders' equity, pays deep-junk credit spreads, and faces a 2027-2028 Xifaxan pricing and patent cliff. The weak trailing GAAP loss is a non-cash impairment artifact rather than an operating collapse; the real question is how much of that cash flow survives the cliff.

Sentiment

fair
Sentiment3
Post-event consolidation

Sentiment is constructive but extended, with recent gains largely absorbed and no immediate catalysts.

The dominant driver is the announced 2026-10-28 Q3 beat-and-raise — adjusted EBITDA above $1B for the first time, FY2026 revenue guidance lifted to $10.975–11.175B — reinforced by a $50M buyback and full redemption of the ~$643M 8.5% 2027 notes, and the measured sentiment delta is a determinate improvement (baseline +0.17 → scoring +0.34/+0.41) with the Red-Flag Screen clean and no cap applied. What keeps this out of the top band is timing rather than tone: the reward is eight days old and largely absorbed, the stock is ~55% higher over October and trading above the only post-print sell-side target, and no forward-dated catalyst sits inside the 30-day window.

Technical

good
Technical4
Strong uptrend

The stock is in a strong uptrend, consolidating after a recent spike, with key levels supporting further gains.

Score 4: trend and momentum are strongly aligned — price 8.34 sits above every key moving average (SMA20 6.79, SMA50 6.33, SMA200 5.72, EMA9 7.68, EMA21 7.03) with MACD 0.58/0.37 (histogram +0.21) and ADX14 33.07 rising from 22.87 five sessions ago, and the planned R/R of 2.00 clears the ≥2.0 top-band criterion. The one weak signal is overbought RSI 71.60 combined with the 2026-10-30 −8.2% reversal off the 9.04 catalyst high and TEMA14 8.41 marginally above spot, which argues for bidding the 8.02–8.14 shelf rather than paying up into 8.46/9.04 resistance — hence 4, not 5.

You’re looking at 2026-11-05 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.